Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Trial of YYC301 for Treatment of Osteoarthritis of the Knee

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03850587
Recruitment Status : Not yet recruiting
First Posted : February 22, 2019
Last Update Posted : March 8, 2019
Sponsor:
Collaborator:
Green Cross Corporation
Information provided by (Responsible Party):
Yooyoung Pharmaceutical Co., Ltd.

Brief Summary:
A Multi-center, Double-blinded, Randomized, Active-controlled, Parallel Design, phaseII Study to Investigate the Efficacy and Safety of YYC301 in Subject With Knee Osteoarthritis

Condition or disease Intervention/treatment Phase
Osteoarthritis, Knee Drug: Celecoxib 200mg Drug: Tramadol 37.5Mg+ Celecoxib 200mg Drug: Tramadol 75mg+ Celecoxib 200mg Drug: Tramadol 150mg+ Celecoxib 200mg Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 252 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: The purpose of this study is to investigate the efficacy and safety after administration of YYC301(Experimental) or Celecoxib(Comparator) in subjects with knee osteoarthritis in a state of uncontrolled pain who took Celecoxib(Cox-2 inhibitor).
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: A Multi-center, Double-blinded, Randomized, Active-controlled, Parallel Design, phaseII Study to Investigate the Efficacy and Safety of YYC301 in Subject With Knee Osteoarthritis.
Estimated Study Start Date : March 3, 2019
Estimated Primary Completion Date : June 3, 2019
Estimated Study Completion Date : October 3, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoarthritis
Drug Information available for: Celecoxib

Arm Intervention/treatment
Experimental: YYC301-1 & Celocoxib placebo

YYC301-1 one capsule and Concomitant Drug Celocoxib placebo.

*YYC301-1 is a capsule. It is composed of Celocoxib 200mg and Tramadol 37.5mg complex).

Drug: Tramadol 37.5Mg+ Celecoxib 200mg
experimental medication

Experimental: YYC301-2 & Celocoxib placebo

YYC301-2 one capsule and Concomitant Drug Celocoxib placebo.

*YYC301-2 is a capsule. It is composed of Celocoxib 200mg and Tramadol 75mg complex)

Drug: Tramadol 75mg+ Celecoxib 200mg
experimental medication

Experimental: YYC301-3 & Celocoxib placebo

YYC301-3 one capsule and Concomitant Drug Celocoxib placebo.

*YYC301-3 is a capsule. It is composed of Celocoxib 200mg and Tramadol 150mg complex)

Drug: Tramadol 150mg+ Celecoxib 200mg
experimental medication

Active Comparator: YYC301 placebo & Celecoxib
Concomitant Drugs with Celecoxib 200mg and YYC301 one capsule.
Drug: Celecoxib 200mg
comparator medication




Primary Outcome Measures :
  1. 100mm Pain VAS [ Time Frame: at 1,4,8,12 weeks after randomization after administration of YYC301(Experimental drug). ]
    Subjects who have severe pain at one-or both sided knee osteoarthritis directly assess the degree of pain (within 24 hours) with a straight line which has 0mm to 100mm. 0 mm means 'doesn't have pain' and 100 mm means 'maximum pain who can imagine'.In order to investigate the degree of subject's pain change from administration of YYC301(Experimental drug).

  2. KOOS(Knee Injury and Osteoarthritis Outcome Score) [ Time Frame: at 4,8,12 weeks after randomization after administration of YYC301(Experimental drug). ]
    KOOS survey is consisted of total 42 questions at 5 groups. 7 questions about symptoms, 9 questions about pain, 17 questions about Function in daily,5 questions about function in sport and recreation(sport/Rec), 4 questions about the knee related quality of life(QoL). Subjects who are participated in this clinical trial, they directly assess these survey with 5 point Likert scale(0~4, 0 means 'nothing' and 4 means 'most severe') and KOOS results are converted to WOMAC score.

  3. Patient Global Assessment(PGA) [ Time Frame: at 4,8,12 weeks after randomization after administration of YYC301(Experimental drug). ]
    Subjects who have been admistrated YYC301 have to directly perform the patient global assessment with 5 point Likert Scale. It has 0 to 5 scales. 0 means 'very poor' and 5 means' very good' In order to investigate the Patient Global point assessment at specific weeks.

  4. Total dosage and dosage rate of rescue treatment. [ Time Frame: at screening time(visit 1; 2 weeks before next visit 2), randomization(visit 2), 4, 8 weeks after randomization. ]
    Subjects who administration of YYC301(Experimental drug) are investigated total dosage and dosage rate of rescue treatment.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Men/Women aged over 20
  • Subjects who are diagnosed with one- or both-sided knee osteoarthritis according to the standards of clinical diagnosis from American College of Rheumatology(ACR)have knee osteoarthritis pain and meet over three of the following conditions.

    1. Older than 50
    2. Morning stiffness for less than 30 minutes
    3. Crepitus on active motion
    4. Bony tenderness
    5. Bony enlargement
    6. Not have heat-generating site
  • Subjects who are diagnosed with degenerative osteoarthritis and have its pain at least for over 3 months before the screening visit.
  • Subjects who are uncontrolled with pain after administration of Celecoxib at least for over 2 weeks before the randomization and have more than 40mm out of 100mm VAS at randomization.
  • Subjects who voluntarily agree to participate in this clinical trial in writing.

Exclusion Criteria:

  • Subjects with rheumatoid arthritis or inflammatory, infectiousand metabolic arthritis.
  • Subjects with ochronosis, hemochromatosis, secondary knee osteoarthritis by systemic disease.
  • Subjects who have severe pain such as Sudek's atrophy, Paget's disease and spinal disc herniation.
  • Subjects with poly-articular affected by severe pain of knee osteoarthritis.
  • Subjects who take psychtrophic medicine and narcotic analgesics for over 3 months that might affect on pain sensory system.
  • Subjects who had Tramadol but there was no improvement in pain.
  • Subjects who got the follwing treatment and medicine before the screening;

    1. Subjects who had surgery on knee ligaments within a year, cartilage transplant and scarf osteotomy.
    2. Subjects who had arthroscopy within 6 months.
    3. Subjects with intra-articular knee joint steroid injection within 3 months.
    4. Subjects with HA injection in knee joint within 2 months.
    5. Subjects with systemic steroid injection within a month(but inhaled steroids)
    6. Subjects with knee replacement surgery.
  • Subjects who hot the following treatment and medicine before the randomization;

    1. Subjects who had Celecoxib, acetaminophen or steroidal/non-steroidal anti-inflammatory drugs except low dose aspirin(before 300mg/day) But, acetaminophen and low dose aspirin (before 300mg/day) are prohibited within 24 hours)
    2. Nutritional supplements, physical therapy and Korean herbal medicine for knee osteoarthritis and it pain within 2 weeks.
  • Subjects who have to take anticoagulant drugs such as warfarin and coumarin during this clinical trial.
  • Subjects who took MAO inhibitors within 14 days before the screening or needed to take these drugs during this clinical trials.
  • Subjects with drug and opioid hypersensitivity and who have history.
  • Subjects with sulfanilamide allergy and who have history.
  • Subjects with asthmma, acute rhinitis, nasal polyp, angioedema, urticaria, allergic reaction to aspirin or any oher NSAIDs(incluing COX-2 inhibitors)
  • Subjects with significant investigations - Hyperkalemia(Exceeded 5.5mmol/L)
  • Subjects with severe liver dysfunction (ALT or AST of more than 3.0 times the upper limit of ULN and 1.5 tmines the upper limit of ULN)
  • Subjects with severe renal impairment (Serum Creatine > 3x ULN).
  • Subjects with active peptic ulcer and gastrointestinal bleeding.
  • Severe blood disease (Agranulocytosis, aplastic anemia, hemolytic anemia, Thrombocytopenia, etc.).
  • Subjects with Crohn's disease or inflammatory bowel disease such as ulcerative clitis.
  • Subjects with congestive heart failure(NYHA 2-4)
  • Subjects with severe ischaemic heart disease, peripheral artery disease and/or cerebrovascular disease.
  • Subjects with genetic problesa such as galactose intolerance), lapp lactase deficiency or glucose-galactose malabsorption).
  • Subjects with acute alcohol intoxification.
  • Subjects who are addicted with took central nervous system drugs such as painkillers, sleeping pills, anti-anxiety medications, etc.
  • Subjects with severe bronchopulmonary dysplasia.
  • Subjects with head injury history of brain structure lesions which may be in danger of mental confusion.
  • Subjects with epilepsy who are treated properly.
  • Subjects who use Tramadol to cure for narcotic withdrawal.
  • Subjects who took other clinical drugs more than once within 30 days before the clinical trial.
  • Subjects suspected to be pregnant who don't agree with the clinical method which is permitted medically during clinical trial(Method of hormone contraception, IUD(Intrauterine device) or IUS(Intrauterine system)), tubal ligation, bilateral tubal ligation(condom, Diaphragm, etc).
  • Pregnant woman and breastfeeding woman.
  • Subjects who can increase risk due to clinical test and administraion of drugs or have severe grade / chronic medical, mental condition or abnormal laboratory result that may interfere with the analysis of thest results.
  • Any other ineligible condition at the direction of investigator that would be ineligible to participate the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03850587


Contacts
Layout table for location contacts
Contact: Min-Kyung Kwon, Manager +82-2-6202-7104 dnminj@yypharm.co.kr
Contact: Min Ji Kim, contact person +82-2-6202-7106 dnminj@yypharm.co.kr

Locations
Layout table for location information
Korea, Republic of
Dong-A University Hospital. Not yet recruiting
Busan, Korea, Republic of
Sub-Investigator: Lip Wang         
Bundang Seoul University Hospital
Seoul, Korea, Republic of
Gachon University Gil Medical Center Not yet recruiting
Seoul, Korea, Republic of
Sub-Investigator: Jae-ang Sim         
Gangnam Severance Hospital
Seoul, Korea, Republic of
Korea University Anam Hospital Not yet recruiting
Seoul, Korea, Republic of
Sub-Investigator: Ki Mo Jang         
Korea University Guro Hospital Not yet recruiting
Seoul, Korea, Republic of
Sub-Investigator: JI Hoon Bae         
Kyung Hee University Hospital at Gangdong
Seoul, Korea, Republic of
KyungHee University Medical Center Not yet recruiting
Seoul, Korea, Republic of
Principal Investigator: Kyung Ho Yoon         
Soonchungyand University Hospital Not yet recruiting
Seoul, Korea, Republic of
Sub-Investigator: Hyeong Suck Choi         
The Catholic University of Korea, Seoul ST. Mary's Hospital.
Seoul, Korea, Republic of
Sponsors and Collaborators
Yooyoung Pharmaceutical Co., Ltd.
Green Cross Corporation

Layout table for additonal information
Responsible Party: Yooyoung Pharmaceutical Co., Ltd.
ClinicalTrials.gov Identifier: NCT03850587     History of Changes
Other Study ID Numbers: YYPCT_YYC301_P2
First Posted: February 22, 2019    Key Record Dates
Last Update Posted: March 8, 2019
Last Verified: February 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Osteoarthritis
Osteoarthritis, Knee
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Celecoxib
Tramadol
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Analgesics, Opioid
Narcotics
Central Nervous System Depressants